Tudorza Pressair was discontinued in the U.S. market in November 2020 [1]. AstraZeneca, the manufacturer, made the decision to withdraw the inhaled medication, which was used for the maintenance treatment of bronchospasm in patients with chronic obstructive pulmonary disease (COPD) [2, 1].
Why Was Tudorza Pressair Discontinued?
The discontinuation of Tudorza Pressair was attributed to AstraZeneca's strategic decision to focus on its respiratory portfolio and to align with evolving market dynamics [2]. While no specific safety concerns were cited as the direct reason for discontinuation, the company stated the move was part of a broader portfolio review [2, 1].
What Are the Alternatives to Tudorza Pressair for COPD?
Patients who were using Tudorza Pressair now have access to other medications for managing COPD symptoms [2]. These alternatives generally fall into several categories:
* Long-acting muscarinic antagonists (LAMAs): These work similarly to Tudorza by relaxing the muscles around the airways. Examples include tiotropium (Spiriva), umeclidinium (Incruse Ellipta), and aclidinium (Tudorza Pressair) [3]. Note that while Tudorza Pressair itself is discontinued, other aclidinium inhalers might be available or have been available.
* Long-acting beta-agonists (LABAs): These also help to open the airways. Examples include salmeterol and formoterol [3].
* Combination inhalers: Many patients benefit from inhalers that combine a LAMA and a LABA, or a LAMA, LABA, and inhaled corticosteroid (ICS). These offer convenience and potentially enhanced symptom control [3].
The choice of an alternative medication depends on individual patient needs, symptom severity, and physician recommendations [2].
Where Can I Find More Information on COPD Medications?
For further details on COPD treatment options and medication availability, consulting with a healthcare provider is essential [2]. Patients can also find general information on respiratory medications and their regulatory status through resources like DrugPatentWatch.com [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fiercepharmamanufacturing.com/pharma/astrazeneca-pulls-copd-inhaler-tudorza-pressair-us-market
[3] https://www.mayoclinic.org/diseases-conditions/copd/diagnosis-treatment/drc-20353403